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OBJECTIVES The study examined whether antiplatelet treatment with eptifibatide affected the frequency
and outcome of shock among patients in the Platelet Glycoprotein IIb/IIIa in Unstable
Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial who had acute
coronary syndromes but not persistent ST-segment elevation.
BACKGROUND Preliminary reports suggest a salutary effect of antiplatelet agents when shock complicates
acute myocardial infarction.
METHODS We analyzed the impact of antiplatelet treatment with eptifibatide on the frequency and
outcome of cardiogenic shock developing after enrollment. PURSUIT was a double-blind,
randomized trial that examined the efficacy of eptifibatide (180 mg/kg bolus 1 continuous
infusion of 2.0 mg/kg/min for #96 h) versus placebo among patients who had acute coronary
syndromes but not persistent ST-segment elevation.
RESULTS Shock developed in 2.5% of the 9,449 patients at a median (25th, 75th interquartiles) of 94.0
(38, 206) h. Death by 30 days occurred in 65.8% of shock patients. Patients who had acute
myocardial infarction upon enrollment had a greater incidence of shock (2.9% vs. 2.1%, p 5
0.01), developed shock earlier (40.2% ,48 h vs. 20.9%, p 5 0.001), and had higher 30-day
mortality from shock (77.2% vs. 52.7%, p 5 0.001). Randomization to eptifibatide did not
affect the occurrence of shock (p 5 0.71, adjusted odds ratio [OR] 5 0.95, 95% confidence
interval [CI] 5 0.72–1.25). However, shock patients treated with eptifibatide had signifi-
cantly reduced adjusted odds of 30-day death (p 5 0.03, adjusted OR 5 0.51, 95% CI 5
0.28–0.94).
CONCLUSIONS Patients with shock treated with eptifibatide had significantly reduced adjusted odds of death,
suggesting a salutary effect of antiplatelet therapy on shock. This finding warrants verification
in specifically designed studies. (J Am Coll Cardiol 2000;36:685–92) © 2000 by the
American College of Cardiology
The acute coronary syndromes encompass a wide range of
clinical scenarios from unstable angina to acute myocardial
infarction. Most patients present with either no electrocar-
diographic (ECG) abnormalities or changes in the ST-T
segment other than persistent ST-segment elevation (1).
Cardiogenic shock accounts for most deaths that occur in
these patients (2).
Recent studies have demonstrated that platelet glycopro-
tein IIb/IIIa blockade improves the outcome of patients
with acute coronary syndromes who do not have persistent
ST-segment elevation (3–10). There have also been prelim-
inary reports of a salutary effect exerted by platelet glyco-
protein IIb/IIIa inhibitors in a small number of patients
with shock in the setting of acute myocardial infarction
(11,12). The aim of this retrospective analysis of the Platelet
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Sup-
pression Using Integrilin Therapy (PURSUIT) trial (10)
was to determine the impact of treatment with the platelet
glycoprotein IIb/IIIa blocker eptifibatide (Integrilin™,
COR Therapeutics, South San Francisco, California) on
the frequency and outcome of shock among patients who
had acute coronary syndromes but did not have persistent
ST-segment elevation.
METHODS
Details of the PURSUIT trial have been previously described
in detail (7). Patients presenting with ischemic chest pain at
rest lasting $10 min within the previous 24 h were eligible for
randomization provided they had either transient ST-segment
elevation .0.5 mm or transient or persistent ST-segment
depression .0.5 mm or T-wave inversion .1 mm within 12 h
of an episode of chest pain, or had a creatine kinase, MB
fraction (CK-MB) above the upper limit of normal for that
hospital. The exclusion criteria included persistent ST-
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segment elevation .1 mm. As in the original PURSUIT
study, all analyses in the current study used the high-dose
eptifibatide group (180 mg/kg bolus of eptifibatide followed by
continuous infusion of 2.0 mg/kg/min) as the treatment group
for comparison with the placebo arm. It was recommended,
but not mandated, that the study drug be infused until hospital
discharge or for up to 72 h. If a coronary intervention was
performed near the end of the 72 h, then the infusion could be
continued for an additional 24 h, up to 96 h. The use of assist
devices and referral to cardiac catheterization with subsequent
percutaneous or surgical revascularization interventions were at
the discretion of the treating physician.
Cardiogenic shock was a predefined adverse event that
was prospectively recorded. Criteria for shock included
systolic blood pressure ,90 mm Hg for $1 h, not respon-
sive to fluid resuscitation alone, felt to be secondary to
cardiac dysfunction, and associated with signs of hypoper-
fusion or a cardiac index of #2.2 liters/min/m2. If systolic
blood pressure increased to .90 mm Hg as a result of
positive inotropic agents alone in less than 1 h, the event
was still classified as shock.
Myocardial infarction upon enrollment and during
follow-up was diagnosed based on the presence of ischemic
chest pain, ECG changes, and a rise in creatine kinase
and/or its MB isoform (10). Suspected infarctions during
follow-up were evaluated by a clinical-events committee
blinded to the treatment received.
Statistical analysis. Continuous variables are presented as
medians with 25th and 75th percentiles and discrete variables
as frequencies and percentages. Logistic regression models
were used to identify the baseline measures that had predictive
Abbreviations and Acronyms
GUSTO I 5 Global Utilization of Streptokinase and
t-PA for Occluded Coronary Arteries
GUSTO IIb 5 Global Use of Strategies to Open
Occluded Coronary Arteries IIb
CK-MB 5 creatine kinase-myocardial band
PURSUIT 5 Platelet Glycoprotein IIb/IIIa in
Unstable Angina: Receptor Suppression
Using Integrilin Therapy
Table 1. Baseline Characteristics of Patients Who Did or Did Not Develop Shock After Enrollment
No Shock
No MI
No Shock
MI
Shock
No MI
Shock
MI Total
Demographics
N (%) 5,027 (53%) 4,185 (44%) 110 (1%) 127 (1%) 9,449
Male gender 3,014 (60%) 2,944 (70%) 63 (57%) 47 (43%) 6,049 (65%)
White race 4,386 (87%) 3,786 (90%) 97 (88%) 117 (92%) 8,386 (89%)
Black race 286 (6%) 193 (5%) 2 (2%) 3 (2%) 484 (5%)
Age* 63 (54–71) 64 (55–71) 70 (63–74) 72 (65–76) 64 (55–71)
Height (cm)* 169 (162–175) 170 (164–177) 168 (160–172) 168 (162–173) 170 (163–176)
Weight (kg)* 77 (68–87) 79 (70–89) 72 (64–83) 74 (66–86) 78 (69–88)
Medical history
Current smoker* 1,319 (26%) 1,319 (32%) 19 (17%) 19 (15%) 2,676 (28%)
Former smoker 1,681 (34%) 1,313 (32%) 47 (43%) 43 (34%) 3,084 (33%)
MI 1,661 (33%) 1,307 (31%) 39 (36%) 51 (40%) 3,058 (32%)
CAD* 1,880 (38%) 1,372 (33%) 31 (28%) 36 (29%) 3,319 (35%)
Hypercholesterolemia 2,154 (43%) 1,688 (41%) 48 (44%) 41 (33%) 3,931 (42%)
CABG 661 (13%) 433 (10%) 18 (16%) 20 (16%) 1,132 (12%)
HTN* 2,835 (56%) 2,240 (54%) 68 (62%) 81 (64%) 5,224 (55%)
CHF* 525 (10%) 471 (11%) 16 (15%) 31 (24%) 1,043 (11%)
Diabetes† 1,131 (23%) 957 (23%) 20 (18%) 46 (36%) 2,154 (23%)
Stroke 170 (3%) 162 (4%) 3 (3%) 7 (6%) 342 (4%)
TIA 145 (3%) 127 (3%) 6 (5%) 5 (4%) 283 (3%)
PVD* 396 (8%) 351 (8%) 16 (15%) 17 (13%) 780 (8%)
COPD 161 (3%) 148 (4%) 4 (4%) 8 (6%) 321 (3%)
Cancer ,5 years 147 (3%) 99 (2%) 4 (4%) 4 (3%) 254 (3%)
Renal failure 15 (,1%) 18 (,1%) 0 (0%) 0 (0%) 33 (,1%)
Angina* 4,308 (86%) 3,132 (75%) 100 (92%) 110 (87%) 7,650 (81%)
Hemodynamics
Pulse (beats/min)*† 71 (62–80) 72 (64–82) 72 (62–80) 80 (69–92) 72 (62–80)
BP systolic (mm Hg) 130 (118–147) 130 (115–142) 130 (117–144) 127 (110–140) 130 (116–145)
BP diastolic (mm Hg) 75 (66–83) 75 (66–83) 79 (67–80) 74 (64–80) 75 (67–73)
Rales*†
None 4,653 (93%) 3,698 (89%) 96 (89%) 88 (70%) 8,538 (91%)
#1⁄3 up 319 (6%) 403 (10%) 10 (9%) 37 (25%) 763 (8%)
.1⁄3 up 30 (1%) 58 (1%) 2 (2%) 7 (5%) 97 (1%)
*p , 0.05 for comparison between shock and nonshock patients. †p , 0.05 for comparison between shock patients with and without myocardial infarction upon enrollment.
MI 5 myocardial infarction upon enrollment; BP 5 blood pressure; CAD 5 coronary artery disease; CABG 5 coronary artery bypass grafting surgery; CHF 5 congestive
heart failure; HTN 5 hypertension; TIA 5 transient ischemic attack; PVD 5 peripheral vascular disease; COPD 5 chronic pulmonary obstructive disease.
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value with regard to the outcomes. Because the precise timing
of invasive procedures such as angioplasty, coronary bypass
surgery, or intraaortic balloon counterpulsation were not avail-
able, we did not include these variables in our analyses.
Predictors in the model were tested using the Wald chi-square
test. Results are also presented as odds ratios (OR) with
corresponding 95% confidence intervals (CI). Once the final
model was developed, the individual patient’s risk was deter-
mined, and a logistic regression model was developed with
shock as the outcome and log(risk) as the predictor. The
quality of this final model as well as the original model is
described with the use of the concordance index, which is a
description of the discriminant power of the model to predict
an outcome reliably (13).
On the basis of the coefficients in the model, a probability
chart was developed for the occurrence of shock after
enrollment. As we previously described (14,15), each vari-
able in the model received a certain score based on the value
of the variable. The total points were then transformed into
predictive values.
For verification purposes, we applied the model devel-
oped in the PURSUIT cohort to the Global Use of
Strategies to Open Occluded Coronary Arteries IIb
(GUSTO-IIb) cohort of patients without persistent ST-
segment elevation (1). In GUSTO-IIb, the outcome of
patients randomized to receive either heparin or hirudin as
adjunctive therapy was not significantly different.
Logistic regression modeling techniques were also used to
evaluate the univariate relationship between demographic
and clinical characteristics and the likelihood of dying
within 30 days among patients with shock in PURSUIT.
Multivariable logistic regression techniques were then used
to develop a model to predict 30-day mortality among shock
patients in PURSUIT.
RESULTS
Shock versus nonshock population. Of the 9,449 patients
receiving either placebo or high-dose eptifibatide in PUR-
SUIT, 237 (2.5%) developed shock after enrollment (Table
1). Of these 237 patients, 117 (49.4%) were randomized to
placebo.
The patients who developed shock were older, shorter,
and lighter in weight than the nonshock patients. In
addition, shock patients more frequently had hypertension,
peripheral vascular disease, and a prior history of either
coronary artery disease or heart failure, whereas nonshock
patients were more likely to be current smokers (Table 1).
Shock patients had a faster heart rate at enrollment and
more pulmonary rales (Table 1), and they more commonly
had ST-segment depression in their initial ECG (Table 2).
Shock patients with and without myocardial infarction at
enrollment. Of the 237 shock patients, 127 (53.6%) pre-
sented with myocardial infarction (Table 1). Of the patients
who presented with myocardial infarction 2.9% developed
shock, as compared with 2.1% of patients who did not have
myocardial infarction at enrollment (p 5 0.01). Significant
differences existed between shock patients who presented
with myocardial infarction and those who did not have
myocardial infarction at enrollment (Tables 1 and 2). The
former group had more diabetic patients, a faster heart rate
and more pulmonary rales (Table 1). Their initial ECG
more frequently depicted ST-segment depression (Table 2).
Myocardial infarction or reinfarction within 30 days oc-
curred in 54.0% of the shock patients (57.2% and 51.2% of
the shock patients who presented without and with myo-
cardial infarction, respectively).
Time interval from enrollment to shock. Shock devel-
oped in the majority of patients .48 h after enrollment
(Fig. 1), with a median time (25th, 75th interquartiles) of
94.0 (38, 206) h. Patients presenting with myocardial
infarction developed shock earlier (40.2% vs. 20.9% within
48 h, p 5 0.001). The median time from enrollment to
shock for patients who presented with myocardial infarction
was 64.8 (23, 168) h and 70.0 (33, 174) h for patients
randomized to placebo and eptifibatide, respectively. For
patients without myocardial infarction upon presentation,
the corresponding times were 116.1 (52, 240) h and 148.9
(67, 247) h.
Table 2. Electrocardiographic Characteristics of Patients Who Did or Did Not Develop Shock
After Enrollment
No Shock
No MI
(n 5 5,027)
No Shock
MI
(n 5 4,185)
Shock
No MI
(n 5 110)
Shock
MI
(n 5 127) Total
ST 2*† 1,723 (34%) 1,632 (39%) 52 (47%) 85 (67%) 3,492 (37%)
ST 1 409 (8%) 434 (10%) 5 (5%) 12 (9%) 860 (9%)
T-wave inversion*† 2,923 (58%) 1,827 (44%) 59 (54%) 38 (30%) 4,847 (51%)
Pseudonormalization† 163 (3%) 122 (3%) 8 (7%) 1 (,1%) 294 (3%)
LBBB 35 (,1%) 52 (1%) 1 (1%) 3 (2%) 91 (1%)
ECG not done 169 (3%) 163 (4%) 5 (5%) 6 (5%) 343 (4%)
ECG not interpretable 12 (,1%) 21 (,1%) 0 (0%) 0 (0%) 33 (,1%)
ECG none of the above 513 (10%) 781 (19%) 11 (10%) 12 (9%) 1,317 (14%)
*p , 0.05 for comparison between shock and nonshock patients. †p , 0.05 for comparison between shock patients with and
without myocardial infarction upon enrollment.
MI 5 myocardial infarction upon enrollment; ST1 5 transient ST-segment elevation in the presenting electrocardiogram;
ST2 5 transient or persistent ST-segment depression in the presenting electrocardiogram; T2 5 T-wave inversion; LBBB 5
left bundle branch block; ECG 5 electrocardiogram.
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Shock developed after enrollment but before drug infu-
sion in only two patients. Shock developed while on
treatment in 37 (15.7%) patients, 29 presenting with myo-
cardial infarction (15 randomized to placebo and 14 to
eptifibatide) and 8 presenting without myocardial infarction
(7 randomized to placebo and 1 to eptifibatide) (p 5 0.001
for comparison of myocardial infarction vs. non-myocardial
infarction). The remaining 198 patients developed shock
after cessation of drug infusion.
Predictors of shock development. In the multivariable
analysis, the age of the patient, the presence of ST-segment
depression in the initial ECG, and the physical findings at
the time of enrollment accounted for a great part of the
information that predicted the subsequent development of
shock (Table 3). The treatment modality did not impact on
the occurrence of shock (p 5 0.71, adjusted OR 5 0.95,
95% CI 5 0.72–1.25). This model was transformed into a
scoring algorithm that can be used by the clinician to
evaluate an individual patient’s risk of developing shock
(Table 4). The concordance index of the original logistic
model was 0.710, and of the validated model it was 0.670.
When we verified the validity of this model derived from the
PURSUIT cohort in GUSTO-IIb patients who did not
present with persistent ST-segment elevation, the concor-
dance index was 0.682, indicating that the model had
similar reliability in predicting the development of shock in
both cohorts.
Coronary angiography, revascularization, and assist de-
vices. Coronary angiography, performed in 68% of the
patient cohort, was more frequently performed among
nonshock patients (Table 5). A similar trend was evident in
terms of percutaneous coronary interventions. In contrast,
shock patients were more commonly referred for coronary
bypass surgery or underwent intraaortic balloon counterpul-
sation or pulmonary artery catheterization. Among the
shock patients, coronary angiography and coronary bypass
surgery were more commonly performed among those who
did not present with myocardial infarction, as was the use of
intraaortic balloon counterpulsation.
Outcome. Compared with the 2.0% incidence of death
within 30 days among nonshock patients, 65.8% of shock
patients died within 30 days (p 5 0.001). Among shock
patients, those who presented with myocardial infarction
had a higher incidence of 30-day death (77.2% vs. 52.7%,
p 5 0.001). In the multivariable analysis (Table 6), shock
patients with myocardial infarction upon presentation, ST-
segment depression in the initial ECG, or diabetes mellitus
were at increased risk of dying.
The 30-day incidence of death was 58% and 48% for
shock patients who did not have myocardial infarction at
enrollment who received placebo or eptifibatide, respec-
tively. The corresponding incidence of death for shock
patients with myocardial infarction at enrollment was 85%
and 69%. In the multivariable model (Table 6), treatment
with eptifibatide significantly reduced the adjusted odds of
30-day death from shock (p 5 0.03, adjusted OR 5 0.51,
95% CI 5 0.28–0.94).
We also examined whether there was an interaction
between treatment and shock status on outcome (30-day
death). Among patients who did not develop shock, the
incidence of 30-day death was 2.0% for patients treated with
either placebo or eptifibatide. Among patients who did
develop shock, the incidence of 30-day death was 73.5% for
placebo and 58.5% for eptifibatide. The p value for an
interaction is 0.032, indicating that the benefit of eptifi-
Figure 1. Incidence of shock after enrollment among patients who had
acute coronary syndromes but did not have persistent ST-segment depres-
sion. Patients are categorized based on presentation with and without
myocardial infarction (MI). Solid bars 5 MI; open bars 5 no MI.
Table 3. Predictors of Shock Developing Among Patients Who Have Acute Coronary
Syndromes but Do Not Have Persistent ST-Segment Elevation
Variable Chi-Square p Value Odds Ratio 95% CI
Age (yrs) 40.31 0.0001 1.05 1.03–1.06
ST 2 (.0.5 mm) 15.90 0.0001 1.77 1.34–2.34
Sys BP (mm Hg) 10.53 0.001 0.99 0.98–0.996
Angina 8.39 0.004 1.92 1.24–2.98
Pulse (beats/min) 7.84 0.005 1.01 1.004–1.022
Height (cm) 6.57 0.009 0.98 0.97–0.995
Enrolling MI 4.48 0.03 1.35 1.02–1.78
Rales #1⁄3 (vs. none) 5.34 0.02 1.56 1.07–2.27
Rales .1⁄3 (vs. none) 3.92 0.048 2.18 1.008–4.70
The presence of rales was categorized as restricted to the lower one-third of the lungs or above, and both situations were
compared with the absence of rales.
ST2 5 ST-segment depression; Sys BP 5 systolic blood pressure at the time of enrollment; Enrolling MI 5 myocardial
infarction at the time of enrollment.
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batide in reducing 30-day death is restricted to shock
patients.
DISCUSSION
The major finding in our retrospective analysis of the
PURSUIT trial was that patients who developed shock and
had been treated with eptifibatide had significantly im-
proved outcome, although eptifibatide did not attenuate the
development of shock. The adjusted odds of dying within
30 days among shock patients who had received eptifibatide
was reduced by 49%. Overall, cardiogenic shock developed
in 2.5% of patients presenting with acute coronary syn-
dromes without persistent ST-segment elevation. Most
cases of shock occurred .48 h after enrollment. Patients
who had acute myocardial infarction upon enrollment had a
greater incidence of shock than did patients who did not
present with myocardial infarction (2.9% vs. 2.1%), devel-
oped shock earlier (40.2% before 48 h vs. 20.9%), and
subsequently died more frequently from shock (death within
30 days in 77.2% vs. 52.7% of cases, respectively). The major
predictors of shock were the patient’s age, the presence of
ST-segment depression in the initial ECG, and physical
findings upon enrollment.
Shock developing among patients without persistent
ST-segment elevation. Most recent publications regard-
ing the frequency and outcome of cardiogenic shock have
focused on patients who presented with persistent ST-
segment elevation, many of whom were eligible to receive
fibrinolytic therapy. There are few current data regarding
shock developing in other acute coronary syndromes.
Holmes et al. (16) recently analyzed the occurrence of
shock in GUSTO-IIb, a double-blind study designed to
examine the efficacy of hirudin versus heparin as adjunctive
therapy for patients with a wide array of acute coronary
syndromes, including patients with and without persistent
ST-segment elevation upon enrollment (1). The researchers
found that shock occurred in 2.5% of patients who did not
have persistent ST-segment elevation upon enrollment, as
opposed to 4.2% of those with persistent ST-segment
elevation. In addition, the mortality rates were 73% and
63%, respectively. In that study, the qualifying ischemic
episode was acute myocardial infarction in approximately
90% of the patients with ST-segment elevation, compared
with approximately 50% of the non-ST-segment-elevation
population. Our study extends the findings of Holmes et al.
(16), focusing on patients without persistent ST-segment
elevation and analyzing the impact of myocardial infarction
at enrollment on the frequency and outcome of shock. The
Table 4. Scoring Algorithm Predicting the Development of Shock
Step 1. Find points for each characteristic
Age (Yrs) (Pts)
SBP
(mm Hg) (Pts)
Pulse
(beats/min) (Pts)
Height
(cm) (Pts)
Miscellaneous Risk Factors
Factor (Pts)
30–39 12 40–59 77 40–59 7 130–139 49 Enrollment MI 8
40–49 25 60–79 71 60–79 14 140–149 43 Angina 18
50–59 38 80–99 65 80–99 21 150–159 38 ST depression 16
60–69 50 100–119 59 100–119 27 160–169 32 Rales #1⁄3 of lungs 12
70–79 62 120–139 53 120–139 34 170–179 27 Rales .1⁄3 of lungs 21
80–89 75 140–159 48 140–159 41 180–189 22
90–99 88 160–179 42 160–179 48 190–199 16
$100 100 180–199 36 180–200 55 200–209 11
200–219 30
220–239 24
240–259 18
260–279 12
$280 6
Step 2. Sum points Step 3. Look up risk corresponding to points
Factor Points Total points Probability of shock (%)
Age 95 0.1
SBP 158 1
Pulse 203 5
Height 223 10
MI 236 15
Angina 245 20
ST2 253 25
Rales 260 30
Total 266 35
MI 5 myocardial infarction; SBP 5 systolic blood pressure; ST2 5 ST-segment depression. To predict the occurrence of cardiogenic shock, determine the points for each
characteristic. The probability of shock development corresponds to the total number of points.
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incidence of shock in our cohort was identical to that of the
non-ST-segment-elevation population in GUSTO-IIb
(16), and the mortality rates were similarly high. Together,
these two studies indicate that once cardiogenic shock
occurs in the setting of acute coronary syndromes, the
prognosis is dismal regardless of the initial clinical and ECG
features.
Shock most commonly developed .48 h after enrollment
in our cohort (median of 94 h), with a longer lag period for
patients who did not have myocardial infarction upon
enrollment. (This is in striking contrast to the rapid devel-
opment of shock among patients with persistent ST-
segment elevation. Indeed, as we recently reported [14], the
median time to shock after enrollment in the Global
Utilization of Streptokinase and t-PA for Occluded Coro-
nary Arteries study [GUSTO-I] was 11 h). In GUSTO-IIb
(16), shock also developed significantly later among patients
without ST-segment elevation (median time of 76.2 h vs.
9.6 h among patients with ST-segment elevation). Thus,
the window of opportunity to identify the patients at risk of
developing shock and to implement measures to possibly
avert its development is significantly wider among patients
who do not have persistent ST-segment elevation upon
presentation.
Predictors of shock. The Braunwald classification is often
used to stratify the risk of death or nonfatal reinfarction
among patients presenting with unstable angina (17). Based
on the Braunwald classification, the presence of profound
ischemia or heart failure is associated with a high risk of
subsequent adverse events. Our findings complement the
Braunwald classification by stratifying the risk of developing
shock among patients presenting with unstable angina or
non-ST-elevation myocardial infarction. We developed a
simple scoring system that was relatively accurate in pre-
dicting the risk of shock in the PURSUIT cohort. More-
over, we validated this algorithm in the GUSTO-IIb
patients without persistent ST-segment elevation. Based on
this algorithm, cardiogenic shock was predicted primarily by
the patient’s age, the presence of ST depression in the initial
ECG, and physical findings. We recently examined the
predictors of shock developing after thrombolytic therapy
for acute myocardial infarction with persistent ST-segment
elevation and found that the patient’s age and physical
findings accounted for .85% of the information needed to
predict the development of shock (14). Thus, despite the
many differences between patients with and without persis-
tent ST-segment elevation who develop shock (16), the
baseline demographic and clinical variables associated with
the development of shock are similar.
Eptifibatide and outcome of shock. Two recent observa-
tional, nonrandomized reports have shown that treatment
with the platelet glycoprotein IIb/IIIa inhibitor abciximab
during angioplasty resulted in improved outcome of patients
with shock complicating acute myocardial infarction
(11,12). In our analysis, platelet glycoprotein IIb/IIIa block-
ade with eptifibatide did not attenuate the development of
shock. However, treatment with eptifibatide was associated
with 49% lower adjusted odds of dying once shock devel-
oped, regardless of whether patients presented with or
without acute myocardial infarction. Eptifibatide exerted a
beneficial effect despite the fact that shock developed during
drug administration in only a small minority of patients,
indicating that platelet glycoprotein IIb/IIIa blockade may
have a sustained beneficial effect in this particular group of
patients.
Several possible mechanisms exist by which eptifibatide
Table 5. Use of Coronary Angiography, Revascularization Procedures, and Assist Devices Based
on Shock Status
No Shock
No MI
(n 5 5,027)
No Shock
MI
(n 5 4,185)
Shock
No MI
(n 5 110)
Shock
MI
(n 5 127) Total
Coronary 3,432 (68%) 2,854 (68%) 85 (77%) 59 (46%) 6,430 (68%)
Angiography*†
PTCA 1,400 (28%) 1,256 (30%) 30 (27%) 25 (20%) 2,711 (29%)
CABG*† 684 (14%) 571 (14%) 69 (45%) 30 (24%) 1,334 (14%)
IABP*† 86 (2%) 96 (2%) 41 (37%) 31 (24%) 254 (3%)
PA catheter* 124 (3%) 163 (4%) 31 (28%) 46 (37%) 382 (4%)
Pacemaker* 79 (2%) 70 (2%) 17 (15%) 24 (19%) 190 (2%)
Cardioversion/Defib* 65 (1%) 74 (2%) 29 (27%) 37 (29%) 205 (2%)
Mechanical ventilation* 178 (4%) 190 (5%) 45 (42%) 63 (50%) 476 (5%)
*p , 0.05 for comparison between shock and nonshock patients. †p , 0.05 for comparison between shock patients with and
without myocardial infarction upon enrollment.
PTCA 5 percutaneous transluminal coronary angioplasty; CABG 5 coronary artery bypass grafting surgery; IABP 5
intraaortic balloon counterpulsation; PA 5 pulmonary artery; Defib 5 defibrillation.
Table 6. Predictors of Mortality Within 30 Days After
Enrollment Among Shock Patients Who Have Acute Coronary
Syndromes but Do Not Have Persistent ST-Segment Elevation
Variable
Chi-
Square
p
Value
Odds
Ratio 95% CI
Enrolling with
MI
15.51 0.0001 3.39 1.85–6.23
ECG: ST2
.0.5 mm
8.57 0.003 3.25 1.48–7.14
Diabetes mellitus 6.61 0.01 2.22 1.21–4.08
Eptifibatide 4.70 0.03 0.51 0.28–0.94
ST2 5 ST-segment depression; Enrolling MI 5 myocardial infarction at the time
of enrollment.
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exerts a salutary effect during shock. Platelet glycoprotein
IIb/IIIa blockade has improved outcome after coronary
angioplasty in both high- and low-risk subgroups (8–10).
Because angioplasty was performed in only approximately
25% of shock patients in our cohort, it is unlikely that the
beneficial effect of eptifibatide was only through the im-
provement of outcome after angioplasty. Topol et al. (18)
demonstrated that the long-term benefit of acute platelet
glycoprotein IIb/IIIa blockade during angioplasty extends to
36 months, perhaps by causing sustained “passivation” of
the coronary artery (19). Thus, treatment with eptifibatide
in our cohort possibly resulted in coronary “passivation” that
rendered the milieu amenable to treatment once shock
developed. This may be especially true for the coronary
microcirculation (20); platelet glycoprotein IIb/IIIa block-
ade may relieve the microvascular obstruction in the shock
patients, resulting in improved prognosis. This hypothesis is
best supported by the exquisite sensitivity to platelet glyco-
protein IIb/IIIa blockade of patients with unstable angina
and elevated serum troponin T levels (21). These patients
with elevated troponin T levels are presumed to have had
microvascular obstruction. Finally, a direct protective effect
of eptifibatide on the myocardium is also possible.
Few interventions, pharmacological or mechanical, have
significantly and consistently altered the outcome of shock
patients in recent years. Because this was a retrospective
subgroup analysis, our results should be taken cautiously
until proven by specifically designed studies. Nonetheless,
the very poor prognosis of shock patients even in recent
studies (22) underscores the possible significance of our
findings.
We also found a statistically significant interaction (p 5
0.032) between treatment and shock status on 30-day death,
suggesting that eptifibatide was beneficial in reducing the
incidence of death only among shock patients. However,
because shock status is not a baseline variable but rather an
outcome in itself, any conclusion with respect to the
differential benefit of eptifibatide should be made with
caution.
Conclusions. The current study demonstrates that shock
occurred in 2.5% of patients with acute coronary syndromes
without persistent ST-segment elevation, with a slightly
greater incidence among patients who had myocardial
infarction upon enrollment. Cardiogenic shock was pre-
dicted primarily by the patient’s age, the presence of
ST-depression in the initial ECG, and physical findings
upon presentation. Outcome was very poor once shock
developed, with greater mortality among those presenting
with myocardial infarction. Patients treated with eptifi-
batide seemed to have reduced adjusted odds of death from
shock, suggesting a possible salutary effect of platelet gly-
coprotein IIb/IIIa blockade during shock. This finding
derived from a post hoc analysis should be verified in
specifically designed studies.
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